-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $160

Benzinga·06/29/2026 13:58:44
Listen to the news
Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $160.